CC
SYRE icon

Commodore Capital’s Spyre Therapeutics SYRE Stock Holding History

Commodore Capital’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$96.5M Sell
1,912,380
-475,865
-20% -$17.9M 5.58% 5
2025
Q4 		$78.2M Buy
2,388,245
+400,161
+20% +$10.5M 5.21% 5
2025
Q3 		$33.3M Hold
1,988,084
– – 1.63% 23
2025
Q2 		$29.8M Hold
1,988,084
– – 2.1% 19
2025
Q1 		$32.1M Hold
1,988,084
– – 2.36% 16
2024
Q4 		$46.3M Hold
1,988,084
– – 3.39% 11
2024
Q3 		$58.5M Hold
1,988,084
– – 3.65% 10
2024
Q2 		$46.7M Buy
1,988,084
+104,000
+6% +$3.51M 3.19% 13
2024
Q1 		$71.5M Hold
1,884,084
– – 4.78% 5
2023
Q4 		$40.5M Buy
1,884,084
+1,767,760
+1,520% +$24.4M 3.54% 11
2023
Q3 		$1.42M Hold
116,324
– – 0.17% 29
2023
Q2 		$1.31M Buy
+116,324
New +$552K 0.15% 25

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return